Monographie - Ofloxacin

Utolsó frissítés :
14/12/2024

Ofloxacin

Kémiai szerkezet

Kereskedelmi név

A kereskedelmi név meghatározó jelentőségű: a készítmények összetétele országonként, előállítóként eltérő lehet

Anzatax	Malaysia
Floxil	Mexikó
Floxitril	India
Floxstat	Colombia, Ecuador, Mexikó
Istaflox	Mexikó
Menefloks	Törökország
Oflocare	Peru
Oflocet	Marokkó, Portugália, Tunézia
Oflogyl	Venezuela
Ofloxacin	Amerikai Egyesült Államok
Ofloxacine	Franciaország
Ofloxin	Egyiptom
Ofloxol	Malaysia
Surnox	Spanyolország
Tabrin	Görögország
Tarivid	Ausztria, Hollandia, Írország, Lengyelország, Luxemburg, Magyarország, Nagy-Britannia, Németország, Norvégia, Portugália, Svájc, Szaúd-Arábiában, Törökország
Zanocin	India, Lengyelország
Zanovid	India
Zenflox	India

Irodalom : Ofloxacin

	Type	publikáció
59	Napló	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
182	Napló	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
249	Napló	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Napló	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
299	Napló	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Napló	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Napló	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
444	Napló	Bornstein M, Kao SH, Mercorelli M, Verma S. Stability of an ofloxacin injection in various infusion fluids. Am J Hosp Pharm 1992 ; 49: 2756-2760.
889	Napló	Janknegt R, Stratermans T, Cilissen J, Lohman JJHM, Hooymans PM. Ofloxacin intravenous. Compatibility with other antibacterial agents. Pharm Weekbl [Sci] 1991 ; 13: 207-209.
921	Napló	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1410	Napló	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Napló	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Napló	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1481	Napló	Messerschmidt W. Kompatibilität von ofloxacin mit ampicillin. Krankenhauspharmazie 1994 ; 9: 337-340.
1625	Napló	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1668	Napló	Zhang Y, Xu QA, Trissel LA, Williams KY. Compatibility and stability of linezolid injection admixed with three quinolone antibiotics. Ann Pharmacotherapy 2000 ; 34: 996-1001.
1712	Napló	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Napló	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Napló	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	Napló	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1925	Napló	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
2139	Napló	Serrurier C, Chenot ED, Vigneron J, May I, Demor? B. Assessment of injectable drug’s administration in two intensive care units and determination of potential physico-chemical incompatibilities. EJHP Science 2006 ; 12,5: 96-99.
2155	Napló	Battista C, Kane MP, Moon DG, Bailie GR. Stability of ofloxacin in peritoneal dialysis solutions. Perit Dial Int 1995 ; 15: 72-74.
3562	Laboratórium	Ofloxacin (Tarivid®) - Summary of Product Characteristics Sanofi 2014
3791	poszter	Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P. Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y. Apifh Congress, Paris November 2014 2014
3883	Laboratórium	Ceftazidime - Résumé des caractéristiques du produit Arrow 2016

Mentions Légales